Non-alcoholic steatohepatitis (NASH)

Phase 3 Full Data Set Review

Exp Date

Second half of 2020

Amp Volatility Score


Catalyst Info & Data Links


  • Cenicriviroc - Allergan

  • Cotadutide - AstraZeneca

  • Ocaliva - Intercept Pharmaceuticals

  • Resmetirom - Madrigal Pharmaceuticals

  • Selonsertib - Gilead

  • Tropifexor - Novartis


  • ~19 million NASH patients

  • ~16 million  patients with fibrosis due to NASH

  • ~1.5M under Hep/GI care


  • Elafibranor is a dual agonist of the PPARα and PPARδ. Meaning the drug candidate acts simultaneously on the two nuclear receptors, which both play an important role in numerous processes involved in the development of NASH and its co-morbidities (learn more)

Updated by HC

GNFT, Elafibranor, Non-alcoholic steatohepatitis, NASH

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

Do prior negative Seladalpar r...

We started to dig into this question. See our in-process diligence HERE, and share your thoughts. We'd love to hear from you. #GNFT #Elafibranor #NASH #Readout #Seladalpar ...

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon